Rare Cancers – more common than you think
ESMO Video Commentary:
Personalised medicine in head and neck cancers
More than 4.3 million people in the European Union are affected by rare cancers. Despite the rarity of each of the 198 rare cancers, they represent in total about 22% of all cancer cases, including all cancers in children, diagnosed in the EU28 each year.
Rare Cancers Europe (RCE) is a multi-stakeholder initiative dedicated to putting rare cancers firmly on the European policy agenda and to implementing 39 political and stakeholder recommendations.
ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers 2016
Milan, Italy - 25 Nov - 27 Nov 2016 - Find out more here
-
Rare Cancers: The Challenges
- Late or incorrect diagnosis
- Lack of access to appropriate therapies and clinical expertise
- Very limited number of clinical studies due to the small number of patients -
Specific clinical trial methodology needed for rare cancers
RCE calls for new criteria to be used in clinical trials on rare cancer treatments. Read the full article.
-
Rare Cancers: Pathologic Diagnosis
Rare Cancers Europe Consensus Statement summary on the urgent actions needed to improve pathologic diagnosis of rare cancers.
Read the Statement
Latest News
-
15 Sep 2016
Anticancer chemotherapy in teenagers and young adults: managing long term side effects
Information for generalists on late effects of anticancer chemotherapy that may affect quality of life.
-
06 Sep 2016
Improving Outcomes for Children With Rare Cancers
Rare tumour registry created to improve the outcomes of children with rare tumours
-
18 Aug 2016
CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation
The indication concerns the treatment of peripheral T-cell lymphoma